Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of sickle cell anemia (Hgb SS) or sickle-β0-thalassemia (Hgb Sβ0)~* Current episode of ACS, defined as a new lobar or segmental pulmonary infiltrate seen on a chest radiograph and two or more of the following findings:~  1. Temperature of 38.5°C or higher~ 2. Tachypnea (i.e., rapid breathing)~ 3. Dyspnea or increased work of breathing~ 4. Chest wall pain~ 5. Oxygen saturation of less than 90% in room air by pulse oximetry~* Current episode of ACS diagnosed in the 24 hours prior to study entry~* Ability to take medication in capsule form~Exclusion Criteria:~* Prior participation in this study~* Diagnosed with any medical condition that will likely be worsened by corticosteroid therapy, including any of the following conditions:~  1. Diabetes mellitus~ 2. High blood pressure~ 3. Esophageal or gastrointestinal ulceration or bleeding~ 4. Known avascular necrosis~* Diagnosis of ACS in the 6 months prior to study entry~* Treatment with oral or parenteral corticosteroid therapy for any reason in the 14 days prior to study entry~* Use of inhaled corticosteroids or systemic corticosteroids for respiratory illness in the 3 months prior to study entry~* Long-term lung condition that requires treatment with corticosteroids~* Participation in a program of chronic transfusions that ended fewer than 4 months ago. A program of chronic transfusions includes a regimen of serial simple or exchange transfusions given at least every 6 weeks for at least three consecutive transfusions for the prevention of SCD-related complications.~* Pregnant~* Treatment with any investigational drug in the 90 days prior to study entry~* History of either tuberculosis or a positive skin test for tuberculosis~* Known HIV infection or a current systemic fungal infection

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).